1Q23 Business Results
VegzelmaⓇ
✓ In Europe, actively participated in the tender based on its price advantage and the synergy with existing oncology products
✓ Launched in April 2023, it has registered with Medicare and is currently in the process of discussion with PBMs in the US
The global market size of Bevacizumab
41%
24%
Global
Bevacizumab
Market Size
$5.7bn
24%
11%
US
■ Europe
■ Japan
ROW
Note: Market size is as of 2022
Source: IQVIA
Europe
US
Launched in October 2022
Obtained the tender with price and the portfolio advantages
- Received orders from Finland, Italy, and Belgium
- More participation in a tender of other EU countries
Launched in April 2023
- Listed in Medicare
- Negotiating with the number of payers to be registered in the list
1Q23 Business Results
Investor Relations 2023 12
Key Products
Plan & Vision
AppendixView entire presentation